Fiche publication
Date publication
mai 2020
Journal
Revue des maladies respiratoires
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FRAISSE Philippe
Tous les auteurs :
Kassegne L, Bourgarit A, Fraisse P
Lien Pubmed
Résumé
A paradoxical reaction is the worsening of prior existing, or the appearance of, new tuberculous lesions, following the initiation of treatment with anti-tuberculous drugs, after the exclusion of poor compliance, malabsorption, drug interaction or multiresistant mycobacteria. Well known and well managed in the context of HIV coinfection, it is not well known outside this context. An increasing number of publications have described this syndrome. This review aims to describe the pathogenic, epidemiological, clinical, prognostic and therapeutic elements of non-HIV-associated paradoxical reactions. It involves a reversal of the Mycobacterium tuberculosis-induced immunodepression along with a heightened detrimental pro-inflammatory profile caused by efficient drug treatment. Extra-thoracic locations, especially lymph nodes and neurological, malnutrition and initial lymphopenia are the principal risk factors. The median delay is 40±20 days after the onset of treatment. Corticosteroids are the mainstay of the management. Anti-TNF-α drugs show good results in corticosteroid refractory cases. The prognosis is good overall except in neurological forms. The place of preventive methods remains to be established.
Mots clés
Adenopathy, Adénopathie, Anti-TNFα, Anti-tumor necrosis factor α, Immune Reconstitution Inflammatory Syndrome, SRIS, Tuberculoma, Tuberculome, Tuberculose, Tuberculosis
Référence
Rev Mal Respir. 2020 May 5;:
